cbdMD Reports 19% Year-over-Year and 12% Sequential Revenue Growth; Bluebird Acquisition Integration and Medicare BEI Pathway Position Company for Continued Momentum
cbdMD reported Q2 FY26 revenue of $5.6 million, a 19% increase year-over-year and 12% sequentially, driven by core business growth and the integration of Bluebird Botanicals. The company posted a net loss of $0.88 million ($0.08 per share) and an adjusted EBITDA loss of $220,000, though operating losses narrowed compared to the prior year period when excluding acquisition costs.
Key figures
- Revenue
- 5640059
- Revenue Yoy
- 19%
- Dtc sales
- 3800000
- Cash on hand
- 2635243
- Gross profit
- 3256922
- Wholesale sales
- 1800000
- Working capital
- 5400000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.